small molecule

ALUNBRIG

BRIGATINIB

Loss of exclusivityNovember 2035latest FDA-listed patent expiry

CompanyTAKEDA PHARMACEUTICALS USA INC

Drug detail

Brand name	ALUNBRIG
Active ingredient	BRIGATINIB
Strength	180MG
Dosage form	TABLET
Route	ORAL
Modality	Small molecule
FDA approval	October 2017
Marketing status	RX

Listed patents

Patent	Expires	Type
10385078	November 2035	substance, product
9611283	April 2034	use U-2837
9012462	April 2031	substance
9273077	May 2029	use U-2837

Regulatory exclusivity

Code	Expires
ODE-300	May 2027

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from TAKEDA PHARMACEUTICALS USA INC